ScholarIQanswers from OpenAlex & ORCID
Heinz‐Josef Lenz
ResearcherPublications, citations & collaboration network
Heinz‐Josef Lenz is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Heinz‐Josef Lenz have?
ScholarIQindexed works
Heinz‐Josef Lenz has 1,854 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Heinz‐Josef Lenz have?
ScholarIQcitation count
Heinz‐Josef Lenz has 57,776 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Heinz‐Josef Lenz?
ScholarIQh-index
Heinz‐Josef Lenz has an h-index of 107 in OpenAlex.
What is the i10-index of Heinz‐Josef Lenz?
ScholarIQi10-index
Heinz‐Josef Lenz has an i10-index of 533 in OpenAlex.
What is the ORCID of Heinz‐Josef Lenz?
ScholarIQorcid
The ORCID for Heinz‐Josef Lenz is on the source record.
What is the OpenAlex record for Heinz‐Josef Lenz?
ScholarIQopenalex
The OpenAlex for Heinz‐Josef Lenz is on the source record.
What are the most-cited papers on Heinz‐Josef Lenz?
ScholarIQmost cited works
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman, Ray McDermott, Joseph L. Leach, Sara Lonardi, Heinz‐Josef Lenz, Michael A. Morse, Jayesh Desai, Andrew Hill, Michael D. Axelson, Rebecca A. Moss, Monica V. Goldberg, Z. Alexander Cao, Jean-Marie Ledeine, Gregory A. Maglinte, Scott Kopetz, Thierry André
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong, Heinz‐Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Magali Svrcek, Rebecca A. Moss, Jean-Marie Ledeine, Z. Alexander Cao, Shital Kamble, Scott Kopetz, Thierry André
Colorectal cancer
David Cunningham, Wendy Atkin, Heinz‐Josef Lenz, Henry T. Lynch, Bruce D. Minsky, Bernard Nordlinger, Naureen Starling
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer
Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A. Meyerhardt, Deborah Schrag, Claire Greene, Bert H. O’Neil, James N. Atkins, Scott Berry, Blasé N. Polite, Eileen M. O’Reilly, Richard M. Goldberg, Howard S. Höchster, Richard L. Schilsky, Monica M. Bertagnolli, Anthony B. El-Khoueiry, Peter J. Watson, Al B. Benson, Daniel Mulkerin, Robert J. Mayer, Charles D. Blanke
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer
Mark M. Pomerantz, Nasim Ahmadiyeh, Jia Li, Paula Herman, Michael P. Verzi, HarshaVardhan Doddapaneni, Christine A. Beckwith, Jennifer A. Chan, Adam Hills, Matt Davis, Keluo Yao, Sarah M. Kehoe, Heinz‐Josef Lenz, Christopher A. Haiman, Chunli Yan, Brian E. Henderson, Baruch Frenkel, Jordi Barretina, Adam J. Bass, Josep Tabernero, José Baselga, Meredith M. Regan, J. Robert Manak, Ramesh A. Shivdasani, Gerhard A. Coetzee, Matthew L. Freedman